No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 14
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:57:31.660Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Moolec Science S.A. (MLEC) stock was $4.68 as of Oct 6, 2026, 12:38 PM EDT, down 3.70% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -65.0% · 3-year avg -77.7%/yr · 5-year avg -68.1%/yr
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas.
Biotechnology · Grand Cayman, GT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
$-16.50
Revenue
$2.64M
vs Estimate
$4.39M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MLEC | $3.40M | $4.68 | -3.70% | -64.99% | -68.13% | N/A | N/A |
| 2CVKD | $3.42M | $0.96 | +1.50% | -93.24% | N/A | N/A | vs MLEC |
| 3MBIO | $3.49M | $0.46 | +0.16% | -70.71% | -80.80% | N/A | vs MLEC |
| 4EOCN | $3.50M | $3.36 | -2.61% | N/A | N/A | N/A | vs MLEC |
| 5NXL | $3.52M | $4.80 | -11.60% | -79.96% | N/A | N/A | vs MLEC |
| 6AEMD | $3.27M | $6.20 | -4.98% | -83.19% | -78.27% | -65.74% | vs MLEC |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.68
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-7.50 | $-7.50 | $-7.50 | 1 |
| Quarter ending Dec 2026 | $-10.50 | $-10.50 | $-10.50 | 1 |
| Quarter ending Mar 2027 | $-10.50 | $-10.50 | $-10.50 | 1 |
| Quarter ending Jun 2027 | $-9.00 | $-9.00 | $-9.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $6.00 | $6.00 | $6.00 | 1 |
| FY 2028 | $30.00 | $30.00 | $30.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $630000.00 | $630000.00 | $630000.00 | 1 |
| Quarter ending Dec 2026 | $600000.00 | $600000.00 | $600000.00 | 1 |
| Quarter ending Mar 2027 | $650000.00 | $650000.00 | $650000.00 | 1 |
| Quarter ending Jun 2027 | $1.25M | $1.25M | $1.25M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $77.33M | $77.33M | $77.33M | 1 |
| FY 2028 | $130.77M | $130.77M | $130.77M | 1 |
